Tempest Therapeutics Inc Stock

$7.76

3.60%

Nasdaq, Apr 25, 10:00 pm CET

ISIN

US87978U1088

Symbol

TPST

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Tempest Therapeutics Inc Stock price

$7.76

-300.34 97.48% 5Y

Nasdaq, Closing price Fri, Apr 25 2025

-0.29 3.60%

ISIN

US87978U1088

Symbol

TPST

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$27.32m
Enterprise Value	$12.42m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.37
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-42.03m
Free Cash Flow (TTM) Free Cash Flow	$-33.46m
Cash position	$30.27m
EPS (TTM) EPS	$-19.54
P/E forward	negative
Short interest	3.90%

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Get Started for Free Today

Tempest Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Tempest Therapeutics Inc forecast:

1x Buy

33%

2x Hold

67%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Tempest Therapeutics Inc forecast:

Buy

33%

Hold

67%

Analyst Estimates with Stock Price Targets

Financial data from Tempest Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.39 0.39	76% 76% -
Gross Profit	-0.39 -0.39	76% 76% -
- Selling and Administrative Expenses	13 13	54% 54% -
- Research and Development Expense	28 28	62% 62% -
EBITDA	-42 -42	51% 51% -
- Depreciation and Amortization	0.39 0.39	76% 76% -
EBIT (Operating Income) EBIT	-42 -42	44% 44% -
Net Profit	-42 -42	42% 42% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Tempest Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

6 days ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company's novel dual receptor inhibitor of prostagl...

Neutral

GlobeNewsWire

●

18 days ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. Strate...

Neutral

GlobeNewsWire

●

about one month ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial • Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP)

More Tempest Therapeutics Inc News

Company Profile

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.

Head office	United States
CEO	Stephen Brady
Employees	25
Founded	2011
Website	www.tempesttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now